MedTrace Logo

Gene Therapy for Alzheimer's Disease Clinical Trial

NCT00017940 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2009-12-11

No results posted yet for this study

Summary

This Phase I clinical trial is the first step in testing gene therapy. This study is called a "Safety/Toxicity" study by the Food and Drug Administration, and primarily aims to determine whether the experimental protocol is safe for humans. It will determine whether the study procedure causes side effects in humans, and may also give us a preliminary sense of whether this will be effective in combating Alzheimer's disease in humans.

Conditions

  • Alzheimer Disease

Interventions

GENETIC

Human Nerve Growth Factor

Sponsors & Collaborators

Principal Investigators

  • Mark Tuszynski, MD, PhD · University of California, San Diego

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2003-11-30
Completion
2003-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00017940 on ClinicalTrials.gov